Search

Your search keyword '"Matceyevsky, Diana"' showing total 17 results
Start Over Author "Matceyevsky, Diana"
17 results on '"Matceyevsky, Diana"'

1. Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience

Author

Purim, Ofer, Beny, Alexander, Inbar, Moshe, Shulman, Katerina, Brenner, Baruch, Dudnik, Elizabeth, Bokstein, Felix, Temper, Mark, Limon, Dror, Matceyevsky, Diana, Sarid, David, Segal, Amiel, Semenisty, Valeriya, Brenner, Ronen, Peretz, Tamar, Idelevich, Efraim, Pelles-Avraham, Sharon, Meirovitz, Amichay, Figer, Arie, Russell, Kenneth, Voss, Andreas, Dvir, Addie, Soussan-Gutman, Lior, and Hubert, Ayala

Published
2018
Full Text
View/download PDF

5. Contributors

Author

Abrams, Ross A., primary, Adelstein, David J., additional, Alektiar, Kaled M., additional, Alexander, Brian, additional, Alsner, Jan, additional, Altun, Ersan, additional, Anderson, Bethany, additional, Ang, K. Kian, additional, Arthur, Douglas W., additional, Ashman, Jonathan B., additional, Ballo, Matthew T., additional, Barker, Christopher Andrew, additional, Beadle, Beth M., additional, Bedard, Phillipe, additional, Beitler, Jonathan J., additional, Bishop, Michael W., additional, Blackstock, A. William, additional, Bogart, Jeffrey A., additional, Bonner, James A., additional, Bourland, J. Daniel, additional, Bovi, Joseph, additional, Breneman, John, additional, Brito, Juan P., additional, Brown, Paul D., additional, Brundage, Michael D., additional, Buchholz, Thomas A., additional, Burmeister, Bryan Henry, additional, Calderwood, Stuart K., additional, Callister, Matthew D., additional, Calvo, Felipe A., additional, Cannon, George M., additional, Chabner, Bruce A., additional, Chan, Michael D., additional, Chao, Sam T., additional, Charpentier, Anne-Marie, additional, Chung, Christine H., additional, Chung, Peter W.M., additional, Constine, Louis S., additional, Corn, Benjamin W., additional, Covens, Allan, additional, Craciunescu, Oana I., additional, Crane, Christopher H., additional, Creutzberg, Carien L., additional, Crook, Juanita M., additional, Curran, Walter J., additional, Czito, Brian G., additional, Dabaja, Bouthaina S., additional, Das, Shiva, additional, David, Marc, additional, Dawson, Laura A., additional, DeLaney, Thomas F., additional, Devlin, Phillip M., additional, Dewhirst, Mark, additional, Dizon, Don S., additional, Dome, Jeffrey S., additional, Donohue, John H., additional, Duprez, Thierry P., additional, Efstathiou, Jason A., additional, Eisbruch, Avraham, additional, Eisele, David W., additional, Feng, Mary, additional, Fernandes, Rui P., additional, Fielding, Julia R., additional, Fleming, Gini F., additional, Foote, Robert L., additional, Fraass, Benedick A., additional, Freeman, Carolyn R., additional, Garden, Adam S., additional, Gentry, Lindell R., additional, Gien, Lilian T., additional, Gospodarowicz, Mary K., additional, Grau, Cai, additional, Grégoire, Vincent, additional, Greven, Craig M., additional, Greven, Kathryn McConnell, additional, Gunderson, Leonard L., additional, Haddock, Michael G., additional, Halyard, Michele, additional, Hamoir, Marc, additional, Hanna, Timothy Paul, additional, Harari, Paul M., additional, Hay, Ian D., additional, Herman, Joseph M., additional, Holloway, Caroline L., additional, Hong, Theodore Sunki, additional, Horowitz, Neil S., additional, Horseman, Michael R., additional, Howle, Julie, additional, Hrycushko, Brian A., additional, Hsu, David, additional, Hudgins, Patricia A., additional, Hutchinson, Ryan C., additional, Iacobuzio-Donahue, Christine, additional, Izar, Benjamin, additional, Jewells, Valerie L., additional, Jurcic, Joseph Gerard, additional, Kalapurakal, John A., additional, Kavanagh, Brian D., additional, Kelly, Kara M., additional, Khandani, Amir H., additional, Khuntia, Deepak, additional, Kiess, Ana Ponce, additional, Knox, Susan J., additional, Koh, Wui-Jin, additional, Krasin, Matthew J., additional, Kun, Larry E., additional, Laack, Nadia Issa, additional, LaCasce, Ann S., additional, Langer, Corey Jay, additional, Laramore, George E., additional, Lassman, Andrew B., additional, Lawton, Colleen A.F., additional, Lee, Nancy, additional, Lengelé, Benoît, additional, Levin, William P., additional, Lindegaard, Jacob C., additional, Lucas, John T., additional, MacDonald, Shannon M., additional, Mackillop, William J., additional, Mahindra, Anuj, additional, Mancuso, Anthony A., additional, Marcus, Karen Jean, additional, Marks, Lawrence B., additional, Matceyevsky, Diana, additional, Mazeron, Jean-Jacques, additional, McDonald, Mark W., additional, Medin, Paul M., additional, Mehta, Minesh P., additional, Mendenhall, William M., additional, Meredith, Ruby F., additional, Michalski, Jeff M., additional, Milano, Michael T., additional, Minsky, Bruce D., additional, Morrison, William H., additional, Murphy, Erin S., additional, Murthy, Rashmi K., additional, Ng, Andrea K., additional, Nordsmark, Marianne, additional, O'Farrell, Desmond A., additional, Okunieff, Paul, additional, Ove, Roger, additional, Overgaard, Jens, additional, Palta, Manisha, additional, Parker, Alexander S., additional, Pater, Luke E., additional, Peterson, Jennifer L., additional, Pisansky, Thomas M., additional, Potters, Louis, additional, Quon, Harry, additional, Raben, David, additional, Recht, Abram, additional, Rengan, Ramesh, additional, Reyngold, Marsha, Laufer, additional, Riaz, Nadeem, additional, Roberts, Stephen S., additional, Roberts, Kenneth B., additional, Rockhill, Jason K., additional, Rödel, Claus M., additional, Rodriguez-Galindo, Carlos, additional, Rogers, C. Leland, additional, Rosenblat, Todd L., additional, Rule, William G., additional, Russell, Anthony Henryk, additional, Russo, Suzanne, additional, Ryan, David P., additional, Sandlund, John Torsten, additional, Sandow, Pamela L., additional, Sargent, Daniel J., additional, Schild, Steven E., additional, Seegenschmiedt, Michael Heinrich, additional, Shah, Chirag, additional, Shaw, Edward G., additional, Sheehan, Jason P., additional, Sheikh, Arif, additional, Shi, Qian, additional, Siker, Malika L., additional, Small, William, additional, Smith, Benjamin D., additional, Smith, Grace L., additional, Solberg, Timothy D., additional, Stauffer, Paul R., additional, Stevenson, Mary Ann, additional, Stewart, Alexandra J., additional, Suh, John H., additional, Tan, Winston W., additional, Tepper, Joel E., additional, Thomas, Charles R., additional, Thomas, Gillian M., additional, Timmerman, Robert D., additional, Tsang, Richard W., additional, Usuki, Kenneth Y., additional, Valentini, Vincenzo, additional, Valero, Vicente, additional, van den Bent, Martin J., additional, Veness, Michael J., additional, Vicini, Frank A., additional, Vicus, Danielle, additional, Viswanathan, Akila N., additional, Vujaskovic, Zeljko, additional, Wadsworth, J. Trad, additional, Wagner, Henry, additional, Wahl, Daniel R., additional, Warde, Padraig R., additional, Waxweiler, Timothy V., additional, Wehle, Michael J., additional, Weil, Robert J., additional, Weiss, Lawrence M., additional, Werning, John W., additional, Willett, Christopher G., additional, Willey, Christopher Douglas, additional, Wilson, Lynn D., additional, Winkfield, Karen M., additional, Yon-Li, Jennifer, additional, Wolden, Suzanne L., additional, Wong, Terence Z., additional, Wong, Jeffrey Y.C., additional, Wong, William W., additional, Wu, Wenting, additional, Yahalom, Joachim, additional, Yang, Eddy Shih-Hsin, additional, You, Y. Nancy, additional, Zeman, Elaine M., additional, Zeng, Jing, additional, and Zietman, Anthony L., additional

Published
2016
Full Text
View/download PDF

12. Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three‐Weekly Schedule in First‐Line Treatment of Ovarian Cancer.

Author

Safra, Tamar, Waissengrin, Barliz, Levy, Talya, Leidner, Ellie, Merose, Rotem, Matceyevsky, Diana, Grisaru, Dan, Laskov, Ido, Mishaan, Nadav, Shayzaf, Rotem, and Wolf, Ido

Subjects
ANTINEOPLASTIC agents, COMBINED modality therapy, COMPARATIVE studies, DRUG administration, MEDICAL records, OVARIAN tumors, PACLITAXEL, SURVIVAL analysis (Biometry), SYMPTOMS, TREATMENT effectiveness, PROPORTIONAL hazards models, RETROSPECTIVE studies, DESCRIPTIVE statistics, CARBOPLATIN, ACQUISITION of data methodology
Abstract

Background: Conventional first‐line combination therapy for ovarian cancer comprises 6 cycles of adjuvant or neoadjuvant carboplatin (AUC5‐6) with paclitaxel (175 mg/m2) every 3 weeks (PC‐3W). Weekly scheduling of paclitaxel may maximize its antiangiogenic effect and reduce adverse effects. We compared the efficacy and safety of PC‐3W with a modified protocol of weekly paclitaxel 80 mg/m2 and weekly carboplatin AUC2 administered on days 1, 8, and 15 in a 28‐day cycle (i.e., with 1 week off‐treatment [PC‐W]). Materials and Methods: Medical records of consecutive patients treated between 2000 and 2018 were reviewed; 707 patients were analyzed for demographic and clinical characteristics, effectiveness and toxicity. Results: PC‐3W was administered to 402 patients (median age, 60.5 years) and PC‐W to 305 patients (median age, 62.5 years). Most patients (91.4%) were diagnosed at stage III–IV. Notwithstanding a higher proportion of residual disease and older patients in the PC‐W group, median progression‐free survival was 21.4 months and 13.2 months for PC‐W and PC‐3W, respectively; median overall survival was 75.2 and 54.0 months for PC‐W and PC‐3W, respectively. Cox proportional hazards model indicated improved survival for patients treated with PC‐W (hazard ratio, 0.54). Similar results were observed for older patients diagnosed at ≥75 years. PC‐W demonstrated a better safety profile, with lower incidence of neuropathy, neutropenia, and alopecia. Conclusion: PC‐W is as active and better tolerated than the standard PC‐3W regimen. PC‐W may serve as an alternative option for elderly or frail patients. Implications for Practice: Weekly scheduling of paclitaxel 80 mg/m2 and carboplatin AUC2, administered on days 1, 8, and 15 in a 28‐day cycle (PC‐W) for first‐line therapy for advanced ovarian cancer, is as active and better tolerated than the standard regimen of carboplatin and paclitaxel (175 mg/m2) every 3 weeks (PC‐3W). It is possible that the weekly holiday on day 21 in the PC‐W regimen may ensure better completion rates (which may result in treatment delays for toxicity in PC‐3W). The results of this retrospective analysis highlight the weekly regimen as a valid treatment option, especially for elderly patients and those with significant comorbidities. Conventional first‐line combination therapy for ovarian cancer is 6 cycles of adjuvant or neoadjuvant carboplatin with paclitaxel every three weeks. Weekly scheduling of paclitaxel may maximize its antiangiogenic effect and reduce adverse effects. This study compared the efficacy and safety of a weekly versus the three‐weekly protocol in a large cohort of patients with advanced epithelial ovarian cancer. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

13. Phase II national clinical trial of prophylactic irradiation to the contralateral breast for BRCA mutation carriers treated for early breast cancer (EBC).

Author

Evron, Ella, primary, Ben David, Merav A., additional, Goldberg, Hadassah, additional, Fried, Georgeta, additional, Kaufman, Bella, additional, Catane, Rafi, additional, Pfeffer, Rephael, additional, Geffen, David, additional, Karni, Tami, additional, Abdah-Bortnyak, Roxolyana, additional, Rosengarten, Ora, additional, Matceyevsky, Diana, additional, Inbar, Moshe J., additional, Kuten, Abraham, additional, and Corn, Benjamin W., additional

Published
2018
Full Text
View/download PDF

17. Assessing the effectiveness of Dead Sea products as prophylactic agents for acute radiochemotherapy-induced skin and mucosal toxicity in patients with head and neck cancers: a phase 2 study.

Author

Matceyevsky D, Hahoshen NY, Vexler A, Noam A, Khafif A, and Ben-Yosef R

Subjects
Acute Disease, Adult, Aged, Aged, 80 and over, Chemoprevention, Dermatitis etiology, Female, Humans, Israel, Male, Middle Aged, Mineral Waters, Mucositis etiology, Mucous Membrane drug effects, Mucous Membrane radiation effects, Oceans and Seas, Skin drug effects, Skin radiation effects, Dermatitis prevention & control, Emollients therapeutic use, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms radiotherapy, Mouthwashes therapeutic use, Mucositis prevention & control, Treatment Outcome
Abstract

Background: Mucositis and dermatitis are frequently encountered in patients treated with radiochemotherapy. Dead Sea products that contain minerals and other properties have proven effective in treating various skin diseases., Objectives: To evaluate the effectiveness of Dead Sea products in reducing acute radiochemotherapy-induced side effects in patients with head and neck cancer., Methods: In this phase 2 study we compared the outcomes in 24 treated patients and 30 conventionally treated patients matched for age, tumor site, and type of treatment. The Dead Sea products comprised a mouthwash solution (Lenom) and a skin cream (Solaris) used three times daily for 1 week before, during, and up to 2 weeks after completion of radiotherapy. Mucositis and dermatitis were evaluated using common toxicity criteria., Results: Thirteen treated patients (54%) had grade 1-2 and none had 3-4 mucositis, while 17 controls (57%) had grade 1-2 and 4 (13%) had grade 3-4 mucositis. Thirteen treated patients (54%) had grade 1-2 dermatitis; there was no instance of grade 3-4 dermatitis, while 11 patients in the control group (37%) had grade 1-2 and 5 (17%) had grade 3-4 dermatitis. More patients in the control arm needed a break than did patients in the treatment the control arm needed a break than did patients in the treatment arm (P = 0.034)., Conclusions: The two Dead Sea products tested decreased skin and mucosal toxicity in head and neck cancer patients receiving radiochemotherapy.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results